+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2020-2024

  • ID: 5024999
  • Report
  • May 2020
  • Region: Global
  • 120 Pages
  • TechNavio
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Clovis Oncology Inc.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2020-2024

The parp (Poly ADP-ribose Polymerase) inhibitors market is poised to grow by $ 810.23 million during 2020-2024 progressing at a CAGR of 12% during the forecast period. The reports on parp (Poly ADP-ribose Polymerase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the expanded application of PARP inhibitors and increasing patient assistance programs. In addition, expanded application of PARP inhibitors is anticipated to boost the growth of the market as well.

The parp (Poly ADP-ribose Polymerase) inhibitors market analysis includes end-user segment and geographic landscapes.

The parp (Poly ADP-ribose Polymerase) inhibitors market is segmented as below:

By End-User
  • Ovarian cancer
  • Breast cancer
  • Others

By Geographic Landscapes
  • North America
  • Europe
  • APAC
  • South America
  • MEA

This study identifies the ease of administration as one of the prime reasons driving the parp (Poly ADP-ribose Polymerase) inhibitors market growth during the next few years.

The parp (Poly ADP-ribose Polymerase) inhibitors market covers the following areas:
  • Parp (Poly ADP-ribose Polymerase) inhibitors market sizing
  • Parp (Poly ADP-ribose Polymerase) inhibitors market forecast
  • Parp (Poly ADP-ribose Polymerase) inhibitors market industry analysis

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading parp (Poly ADP-ribose Polymerase) inhibitors market vendors that include AbbVie Inc., AstraZeneca Plc, Bayer AG, Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co. Ltd., Johnson & Johnson, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.. Also, the parp (Poly ADP-ribose Polymerase) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

This study presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.

The market research report provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Clovis Oncology Inc.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc

Executive Summary
  • Market Overview

Market Landscape
  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing
  • Market definition
  • Market size 2019
  • Market segment analysis
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by End-user
  • Market segments
  • Comparison by End-user
  • Ovarian cancer - Market size and forecast 2019-2024
  • Breast cancer - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by End user

Customer landscape
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape
  • Overview
  • Vendor Landscape
  • Landscape disruption

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Clovis Oncology Inc.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Johnson & Johnson
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2019 - 2024 ($ million)
13: Global market: Year-over-year growth 2019 - 2024 (%)
14: Five forces analysis 2019 & 2024
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2019
21: End user - Market share 2019-2024 (%)
22: Comparison by End user
23: Ovarian cancer - Market size and forecast 2019-2024 ($ million)
24: Ovarian cancer - Year-over-year growth 2019-2024 (%)
25: Breast cancer - Market size and forecast 2019-2024 ($ million)
26: Breast cancer - Year-over-year growth 2019-2024 (%)
27: Others - Market size and forecast 2019-2024 ($ million)
28: Others - Year-over-year growth 2019-2024 (%)
29: Market opportunity by End user
30: Customer landscape
31: Market share by geography 2019-2024 (%)
32: Geographic comparison
33: North America - Market size and forecast 2019-2024 ($ million)
34: North America - Year-over-year growth 2019-2024 (%)
35: Europe - Market size and forecast 2019-2024 ($ million)
36: Europe - Year-over-year growth 2019-2024 (%)
37: APAC - Market size and forecast 2019-2024 ($ million)
38: APAC - Year-over-year growth 2019-2024 (%)
39: South America - Market size and forecast 2019-2024 ($ million)
40: South America - Year-over-year growth 2019-2024 (%)
41: MEA - Market size and forecast 2019-2024 ($ million)
42: MEA - Year-over-year growth 2019-2024 (%)
43: Key leading countries
44: Market opportunity by geography ($ million)
45: Impact of drivers and challenges
46: Vendor landscape
47: Landscape disruption
48: Industry risks
49: Vendors covered
50: Market positioning of vendors
51: AbbVie Inc. - Overview
52: AbbVie Inc. - Business segments
53: AbbVie Inc. - Key offerings
54: AbbVie Inc. - Key customers
55: AbbVie Inc. - Segment focus
56: AstraZeneca Plc - Overview
57: AstraZeneca Plc - Business segments
58: AstraZeneca Plc - Key offerings
59: AstraZeneca Plc - Key customers
60: AstraZeneca Plc - Segment focus
61: Bayer AG - Overview
62: Bayer AG - Business segments
63: Bayer AG - Key offerings
64: Bayer AG - Key customers
65: Bayer AG - Segment focus
66: Clovis Oncology Inc. - Overview
67: Clovis Oncology Inc. - Business segments
68: Clovis Oncology Inc. - Key offerings
69: Clovis Oncology Inc. - Key customers
70: Clovis Oncology Inc. - Segment focus
71: Daiichi Sankyo Co. Ltd. - Overview
72: Daiichi Sankyo Co. Ltd. - Business segments
73: Daiichi Sankyo Co. Ltd. - Key offerings
74: Daiichi Sankyo Co. Ltd. - Key customers
75: Daiichi Sankyo Co. Ltd. - Segment focus
76: GlaxoSmithKline Plc - Overview
77: GlaxoSmithKline Plc - Business segments
78: GlaxoSmithKline Plc - Key offerings
79: GlaxoSmithKline Plc - Key customers
80: GlaxoSmithKline Plc - Segment focus
81: Jiangsu Hengrui Medicine Co. Ltd. - Overview
82: Jiangsu Hengrui Medicine Co. Ltd. - Business segments
83: Jiangsu Hengrui Medicine Co. Ltd. - Key offerings
84: Jiangsu Hengrui Medicine Co. Ltd. - Key customers
85: Jiangsu Hengrui Medicine Co. Ltd. - Segment focus
86: Johnson & Johnson - Overview
87: Johnson & Johnson - Business segments
88: Johnson & Johnson - Key offerings
89: Johnson & Johnson - Key customers
90: Johnson & Johnson - Segment focus
91: Pfizer Inc. - Overview
92: Pfizer Inc. - Business segments
93: Pfizer Inc. - Key offerings
94: Pfizer Inc. - Key customers
95: Pfizer Inc. - Segment focus
96: Teva Pharmaceutical Industries Ltd. - Overview
97: Teva Pharmaceutical Industries Ltd. - Business segments
98: Teva Pharmaceutical Industries Ltd. - Key offerings
99: Teva Pharmaceutical Industries Ltd. - Key customers
100: Teva Pharmaceutical Industries Ltd. - Segment focus
101: Currency conversion rates for US$
102: Research Methodology
103: Validation techniques employed for market sizing
104: Information sources
105: List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Clovis Oncology Inc.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
The publisher recognizes the following companies as the key players in the global parp (poly adp-ribose polymerase) inhibitors market: AbbVie Inc., AstraZeneca Plc, Bayer AG, Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co. Ltd., Johnson & Johnson, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is ease of administration."

According to the report, one of the major drivers for this market is the expanded application of PARP inhibitors.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Clovis Oncology Inc.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Johnson & Johnson
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown